CA3171709A1 - T-cell bispecific binding proteins - Google Patents
T-cell bispecific binding proteins Download PDFInfo
- Publication number
- CA3171709A1 CA3171709A1 CA3171709A CA3171709A CA3171709A1 CA 3171709 A1 CA3171709 A1 CA 3171709A1 CA 3171709 A CA3171709 A CA 3171709A CA 3171709 A CA3171709 A CA 3171709A CA 3171709 A1 CA3171709 A1 CA 3171709A1
- Authority
- CA
- Canada
- Prior art keywords
- bispecific
- amino acid
- seq
- antibody
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062990281P | 2020-03-16 | 2020-03-16 | |
| US62/990,281 | 2020-03-16 | ||
| PCT/US2021/022626 WO2021188590A2 (en) | 2020-03-16 | 2021-03-16 | T-cell bispecific binding proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3171709A1 true CA3171709A1 (en) | 2021-09-23 |
Family
ID=77768281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3171709A Pending CA3171709A1 (en) | 2020-03-16 | 2021-03-16 | T-cell bispecific binding proteins |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230183344A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4121462A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023520636A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115667314A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021239929A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3171709A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021188590A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024131861A1 (en) * | 2022-12-21 | 2024-06-27 | Erasmus University Medical Center Rotterdam | Bispecific antibodies targeting cd117 and cd3 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN119241716B (zh) * | 2024-09-13 | 2026-05-19 | 杭州百瑞竞康生物技术有限公司 | 结合CD235a和CD3的融合蛋白及其制备方法和用途 |
| CN119874942B (zh) * | 2025-03-28 | 2025-09-26 | 核欣(苏州)医药科技有限公司 | 一种放射性蛋白偶联药物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050159T2 (hu) * | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| EP3105252B1 (en) * | 2014-02-12 | 2019-07-24 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| ES2823033T3 (es) * | 2015-05-28 | 2021-05-05 | Genentech Inc | Ensayo basado en células para detectar homodímeros anti-CD3 |
| TWI796283B (zh) * | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
| IL258491B2 (en) * | 2015-10-16 | 2023-09-01 | Univ Columbia | Preparations and methods for inhibiting antigens of a particular lineage |
| EP3408671B1 (en) * | 2016-01-25 | 2023-11-01 | F. Hoffmann-La Roche AG | Methods for assaying t-cell dependent bispecific antibodies |
| US10538579B2 (en) * | 2016-08-15 | 2020-01-21 | Board Of Regents, The University Of Texas System | Bispecific pertussis antibodies |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| US10882915B2 (en) * | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| EP3700568A4 (en) * | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| WO2019084053A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| CN113330026A (zh) * | 2018-10-23 | 2021-08-31 | 美真达治疗公司 | Fc沉默的抗体药物缀合物(ADC)及其用途 |
| GB201912681D0 (en) * | 2019-09-04 | 2019-10-16 | Eth Zuerich | Bispecific binding agent that binds to cd117/c-kit and cd3 |
-
2021
- 2021-03-16 EP EP21771456.7A patent/EP4121462A4/en active Pending
- 2021-03-16 CA CA3171709A patent/CA3171709A1/en active Pending
- 2021-03-16 JP JP2022555860A patent/JP2023520636A/ja active Pending
- 2021-03-16 WO PCT/US2021/022626 patent/WO2021188590A2/en not_active Ceased
- 2021-03-16 CN CN202180035812.8A patent/CN115667314A/zh active Pending
- 2021-03-16 AU AU2021239929A patent/AU2021239929A1/en not_active Abandoned
- 2021-03-16 US US17/906,471 patent/US20230183344A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021239929A1 (en) | 2022-10-13 |
| US20230183344A1 (en) | 2023-06-15 |
| CN115667314A (zh) | 2023-01-31 |
| EP4121462A2 (en) | 2023-01-25 |
| EP4121462A4 (en) | 2024-04-24 |
| JP2023520636A (ja) | 2023-05-18 |
| WO2021188590A3 (en) | 2022-07-21 |
| WO2021188590A2 (en) | 2021-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230183344A1 (en) | T-cell bispecific binding proteins | |
| CN109715667B (zh) | 抗-gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子及其用途 | |
| TWI805109B (zh) | 對cd19具專一性之抗體及嵌合抗原受體 | |
| TWI819458B (zh) | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 | |
| CN107660214B (zh) | 针对cd3和cd20的双特异性抗体 | |
| CN103282383B (zh) | 抗cd38抗体 | |
| US20250326856A1 (en) | Humanized anti-cd45 antibodies and uses thereof | |
| WO2019084067A1 (en) | ANTI-CD117 ANTIBODIES AND METHODS OF USE | |
| TW202126682A (zh) | 針對ror1之特異性抗體及嵌合抗原受體 | |
| US20220023348A1 (en) | Genetically modified hspcs resistant to ablation regime | |
| US20100303808A1 (en) | Humanized anti-cd20 antibodies and methods of use | |
| JP2023545099A (ja) | 三重特異性バインダー | |
| US20230144405A1 (en) | Human anti-cd33 antibodies and uses thereof | |
| KR20240115920A (ko) | 세포 치료에 이용하기 위한 cd117의 식별 가능한 세포 표면 단백질 변이체 | |
| JP2024528935A (ja) | 抗cd38抗体、抗cd3抗体、及び二重特異性抗体、並びにその使用 | |
| JP2022538461A (ja) | Cd38およびcd3に結合するヘテロ二量体抗体 | |
| KR20240119146A (ko) | 세포 치료에 이용하기 위한 cd45의 식별 가능한 세포 표면 단백질 변이체 | |
| WO2019084053A1 (en) | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS | |
| EP4592319A1 (en) | Antibodies capable of specifically binding tnf-like ligand 1a and use thereof | |
| TW202606758A (zh) | 抗cd74抗體組合物及方法 | |
| WO2025264864A1 (en) | Human anti-cd45 antibodies and uses thereof | |
| HK40129548A (en) | Antibodies capable of specifically binding tnf‑like ligand 1a and use thereof | |
| WO2026096570A1 (en) | Hybrid anti-cd20 car t cell therapy for the treatment of autoimmune diseases | |
| CN120958019A (zh) | 针对人分化簇3蛋白的抗体及其变体 | |
| HK40049993A (en) | Antibodies and chimeric antigen receptors specific for cd19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250902 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251103 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260202 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260402 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260428 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260709 |